Your session is about to expire
← Back to Search
Unknown
ABBV-CLS-7262 for Healthy Subjects
Phase 1
Waitlist Available
Research Sponsored by Calico Life Sciences LLC
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up two weeks
Awards & highlights
No Placebo-Only Group
Summary
This trial tests how a new drug (ABBV-CLS-7262) interacts with common medications for cholesterol and heart conditions. Participants will take these drugs in different combinations to see how they work together.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ two weeks
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~two weeks
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Pharmacokinetics of Digoxin
Pharmacokinetics of Rosuvastatin
Secondary study objectives
Safety and Tolerability
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: ABBV-CLS-7262Experimental Treatment1 Intervention
ABBV-CLS-7262 + Digoxin + Rosuvastatin
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
ABBV-CLS-7262
2023
Completed Phase 1
~110
Find a Location
Logistics
Participation is compensated
You will be compensated for participating in this trial.
Who is running the clinical trial?
Calico Life Sciences LLCLead Sponsor
9 Previous Clinical Trials
815 Total Patients Enrolled
AbbVieIndustry Sponsor
1,023 Previous Clinical Trials
520,277 Total Patients Enrolled
Other Trials to Consider
Popular Categories
Learn More About These Treatments
Share this study with friends
Copy Link
Messenger